International Journal for the Study of New Religions
March 23, 2022
Anna Lutkajtis
3 citations
Recently there has been a surge of renewed interest in the psychedelic compound psilocybin. In particular, psilocybin is being studied in clinical settings as a potential breakthrough treatment for depression. Alongside this growing therapeutic interest, there has been a rise in the religious use of psilocybin, as evidenced by the creation of a number of psilocybin mushroom churches in the...
Frontiers in Epidemiology
March 23, 2022
Alan K. Davis, Brooke J. Arterberry, Yitong Xin et al.
20 citations
Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods Data came from the 2015–2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( n = 41,060; female = 40.4%). Descriptive and multinomial logistic...
Journal of Psychoactive Drugs
March 23, 2022
Mitch Earleywine, Fiona Low, Brianna R. Altman et al.
31 citations
Promising outcomes of Psilocybin-Assisted Therapy (PAT) for depression have generated concerted efforts to replicate, extend, and refine protocols to maximize efficacy. Psychotherapy research reveals that clients benefit most when important components of treatment align with their personal preferences. One open question related to PAT concerns the importance of the psilocybin experience of the...
Frontiers in Pharmacology
March 22, 2022
Enzo Tagliazucchi
20 citations
Psychedelics are drugs capable of eliciting profound alterations in the subjective experience of the users, sometimes with long-lasting consequences. Because of this, psychedelic research tends to focus on human subjects, given their capacity to construct detailed narratives about the contents of their consciousness experiences. In spite of its relevance, the interaction between serotonergic...
Cambridge University Press eBooks
March 20, 2022
Timmen Cermak
Jackson was bored with his massage therapy practice and was looking for something more interesting to do. Cannabis legalization had reawakened his interest in the use of natural, psychoactive substances as healing and spiritual agents. A once-a-month user of cannabis, he was enthusiastic about Johns Hopkins University’s research on the potential mental health benefits of psilocybin, the...
Journal of Counseling & Development
March 19, 2022
Benjamin Hearn, Michael D. Brubaker, George B. Richardson
46 citations
Abstract The ‘‘psychedelic renaissance’’ is generating new evidence for psychedelics’ potential to treat numerous mental and substance use disorders. In particular, the United States Food and Drug Administration is poised to approve psychedelic drugs 3,4 methylenedioxymethamphetamine (MDMA) and psilocybin for the use in psychedelic‐assisted therapy (PAT). This renaissance has led to substantial...
Australian & New Zealand Journal of Psychiatry
March 12, 2022
Steve Kisely, Mark Connor, Andrew A Somogyi et al.
36 citations
Objectives: There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed,...
Metabolic Engineering Communications
March 11, 2022
Alexandra M. Adams, Nicholas A. Anas, Abhishek K. Sen et al.
21 citations
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a...
March 11, 2022
William E. Schreiber
This chapter highlights the similarities in chemical structure and physiologic effects of hallucinogens, as well as their metabolism, therapeutic uses and potential for misuse or abuse. Special attention is given to the testing process, with an emphasis on interpretation of test results. Hallucinogens are drugs that alter an individual's perception of reality. The classic hallucinogens include...
Journal of Fungi
March 11, 2022
Elaine Meade, Sarah Hehir, Neil J. Rowan et al.
24 citations
Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these...
Frontiers in Pharmacology
March 9, 2022
Drummond E-Wen Mcculloch, Maria Zofia Grzywacz, Martin Bruun Madsen et al.
91 citations
Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study (NCT03289949), 35 medium-high doses of psilocybin were administered to 28...
Research Square
March 8, 2022
Gabriella Smedfors, Elliot J. Glotfelty, Negar Kalani et al.
8 citations
preprint
Abstract Psilocybin is a psychedelic substance approaching clinical use. The drug has long-lasting effects after single or multiple administrations and enhances structural plasticity in the brain. Little is known if the plasticity inducing effects of psilocybin could be timed to other treatments and promote a larger effect. We investigated the effect of psilocybin on cultured mouse hippocampal...
Psychopharmacology
March 7, 2022
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm et al.
85 citations
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.
Frontiers in Psychology
March 4, 2022
Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan
27 citations
Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...
Psychopharmacology
March 2, 2022
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
30 citations
Time underestimation produced by (S)-ketamine could be associated with its antidepressant effects; however, it was accompanied with severe behavioral disruption. We also hypothesize that behavioral disruption produced by psychedelics objectively reflects their psychotomimetic-like actions.
medRxiv
March 2, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
preprint
Abstract Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy...
Der Nervenarzt
March 1, 2022
Gerhard Gründer, Manuela Brand, Laura Kärtner et al.
Psychedelics, such as psilocybin represent one of the most promising current therapeutic approaches in psychiatry. Psychedelics seem to have not only potent antidepressant effects. Do they also work particularly quickly, i.e. within one day? The available literature on clinical studies of psychedelics in depressive syndromes is presented both from the period up to the prohibition of these...
Journal of Psychopharmacology
March 1, 2022
Max Wolff, Lea J. Mertens, Marie Walter et al.
57 citations
Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...
Journal of Psychoactive Drugs
February 28, 2022
Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al.
47 citations
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...
Expert Opinion on Drug Safety
February 26, 2022
Jan Van Amsterdam, Wim van den Brink
74 citations
Psilocybin - mostly combined with psychotherapy or psychotherapeutic support - shows a promise as a treatment for various (treatment-resistant) mental disorders. Larger double-blind RCTs with objective (long-term) outcomes are needed to confirm these findings before standard clinical use of psilocybin can be considered.